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Abstract
Cerebrovascular  diseases  are  currently  among  the  three  primary  causes  of  death
worldwide and are the first cause of disability in adults. Nevertheless, there are no
neuroprotective or neurorestorative therapies that have shown considerable beneficial
effects, except for the FDA-approved recombinant tissue plasminogen activator (rtPA),
which has been used for decades for the treatment of stroke and its effectiveness is still
controversial. This is why it is very important to develop effective therapeutic options.
In order to achieve this objective, it is essential to recognize the secondary mechanisms
involved in the pathological development. The immunological system is one of these
mechanisms that participate during the acute and chronic phases of disease, both in
deleterious and beneficial  manners.  It  is  known that  the immune system’s duality
contributes to the ischemic injury through proinflammatory cytokine (tumor necrosis
factor-α (TNF-α), interleukin-1 (IL-1), interleukin-6 (IL-6)), and oxygen reactive species
production, etc. Nevertheless, it also provides protection and even restoration through
anti-inflammatory cytokine (interleukin-4 (IL-4), interleukin-10 (IL-10), transforming
growth factor-β (TGF-β)), and growth factor (brain-derived neurotrophic factor (BDNF),
insulin-like  growth factor-1  (IGF-1),  neurotrophin-3  (NT-3),  neurotrophin-4  (NT-4))
production. This states that innovative therapeutic options must be proposed with the
goal of protecting and restoring the tissue after the ischemic event. Such therapies are
exposed in the present chapter.
Keywords: cerebral ischemia, neuroprotection, immunomodulation, inflammation
protective autoimmunity, neurorestoration
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1. Introduction
Cerebrovascular diseases (CVD) include hemorrhagic and ischemic brain injuries, the latter
being the most common since 85% of cases arise from atherothrombotic (artery stretching)
and  atheroembolic  etiologies.  Both  of  these  diseases  are  the  first  cause  of  permanent
disabilities  in adults,  primarily in developed countries,  where 30% of patients that  have
suffered from stroke become incapable of performing their daily routines [1]. Stroke is, in
addition, among the first three causes of premature death worldwide; according to the World
Health Organization (WHO), 6.7 million deaths were caused by cerebral ischemia in 2012, as
well as 46% of deaths being caused by stroke and ischemic heart disease altogether, with
mayor incidence in low-income countries, with 80% of cases [2]. As for the United States
(which has the most available information), the American Heart Association (AHA) reported
in an updated statistics report that the death rates associated with stroke have been dropping
over the years, and from 2009 to 2012, the prevalence is estimated in 2.6% with an incidence
of almost 800,000 cases a year, one every 40 s [3]. And according to the Center for Disease
Control (CDC), there is one death out of every 20 stroke cases, or one every 4 min [4]. On the
other  hand,  European  countries  experience  dramatic  differences  in  disease  burden.  The
EuroHOPE study performed on data from 2007 observed higher incidence of ischemic stroke
in Hungary, and Finland and less in Scotland and Sweden and different mortality rates among
regions in different countries [5].
The incidence and prevalence of stroke and its recurrence continue to be high due to the low
attention and awareness to symptoms which create delay in the seeking of medical attention,
allowing damage to progress. People are not aware that time is critical for stroke treatment
due to the short therapeutic window of available treatments. Disabilities and dependence
among patients tend to get worse in the 6–12 months following stroke; mobility and function-
ality related to dressing and toileting are the most affected, and deterioration is related to prior-
to-stroke comorbidities [6]. Depression is one of the major outcomes and is associated with
stroke recurrence [7].
There are a vast array of risk factors associated with cerebrovascular diseases and specifical-
ly to cerebral ischemia. The most common are chronic diseases that could be modified
through behavioral and lifestyle changes or pharmacological treatment such as diabetes, hy-
pertension, obesity, and atherosclerosis; besides, alcoholism and tabaquism, high salt con-
sumption, and sedentarism are behaviors that are associated with a greater risk of
developing stroke [2]. On the other hand, there are a series of risk factors that cannot be
controlled and predispose a person to cerebral ischemia: they are age, gender, and ethnicity.
For instance, postmenopausal women have greater risk of developing stroke than men the
same age, but premenopausal women are protected by estrogenic hormones [8, 9]. It has
also been reported in 2010 by the Global Burden of Disease (GBD) that 31% of strokes are
among young adults (20–64 years of age) and strokes are common in people below 45 years
of age [10]. Non-Caucasians are also at greater risk of stroke than Caucasians [8].
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2. Pathophysiology
Usually, when speaking about stroke, two stages of damage to the integrity of the neural tissue
are considered. The first stage is the lesion per se, caused by the restriction of blood flow from
an obstruction in a major vessel and presents the characteristic physiopathology that ends in
neural death. This area of the lesion, which is almost immediately damaged at this stage is
called the “infarct core.” The second stage of damage is that of secondary degeneration that
further injures tissue not originally damaged by the restricted blood flow, but that is adjacent
to and surrounds the infarct core. This area of lesion is called “ischemic penumbra,” it preserves
some energy metabolism, and its degeneration is caused primarily by excitotoxicity and
inflammation.
Nonetheless, inflammation previously contributes to the development of stroke, since people
who suffer from chronic proinflammatory state diseases like hypertension, dyslipidemia,
atherosclerosis, and type-two diabetes have endothelial alterations, as well as irregularities in
rheology and hemodynamics [11]. Galectin-3 (GAL-3) concentration is increased in these
patients; this protein favors atherosclerotic plaque formation and might participate in the
development of cerebrovascular disease [12] GAL-3 is also a very important inflammatory and
fibrogenic mediator [13, 14]. Interleukin-1β (IL-1β) is a proinflammatory cytokine that has been
related to atherosclerotic plaque formation and vascular inflammation [15]; other factors have
also been associated with it, such as Von Willebrand coagulation factor, selectin E, and others
[16].
Atherosclerotic plaque is characterized by accumulation of molecules of cholesterol and low-
density lipoproteins (LDL) in the vessel walls, after being oxidized they chemo-attract
monocytes to the site, and they phagocytose these oxidized LDL, which in turn causes them
to become foam cells. Foam cells loaded with high amounts of LDL stay trapped in the
endothelium and suffer from apoptosis and necrosis. This situation generates a lipidic plaque
covered by connective tissue and are infiltrated by activated T cells, macrophages and
mastocytes that will chronically produce inflammatory mediators in the endothelial wall [17].
Oxidized cell and molecule accumulation generate endothelial wall activation, thus promoting
adhesion molecule expression and easing immune cell aggregation.
Several investigators consider that the severity of endothelial inflammation can imply
differences in atherosclerotic plaque rupture vulnerability, which will contribute to the
development of ischemia in the surrounding tissue. For this reason, the use of imaging
technology such as Computerized axial tomography Computerized axial tomogra-
phy(CAT);Positron emission tomography (PET) scan, MRI, and Positron emission tomography
(PET), has been considered in order to identify the degree of endothelial inflammation and to
assess risk of developing an ischemic event [18].
Stroke originates from either a reduction in the arterial lumen, or the release of a thrombus
that becomes trapped in a major artery, most commonly the middle cerebral artery (MCA).
This occlusion causes diminished blood flow to the site irrigated specifically by that vessel and
so glucose and oxygen supply will stop, triggering metabolic insufficiency. The incapacity for
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glucose to reach the cells causes a decrease in adenosine triphosphate (ATP) production which
interferes with Na+ and K+ pump function; in light of this, intracellular K+ decreases dramati-
cally causing membrane depolarization [19], and thus, further voltage-dependent Ca2+ channel
dysfunction and opening, unlocking of some CA2++ receptor-dependent channels, Na+/Ca2+
channels from cellular and mitochondrial membrane, and CA2+ pump deterioration in cell
membrane, and endoplasmic reticulum [20].
All of these events triggered by membrane depolarization drive a secretion of excitatory
neurotransmitters, especially glutamate that upon binding to its receptors induces greater
depolarization and glutamate release, giving rise to the excitotoxicity phenomenon [21]. The
massive amounts of calcium will activate a series of enzymes (e.g., calpaines, phospholipases,
and endonucleases), and free radicals that in turn lead to neuronal death.
On the other hand, the proinflammatory milieu that is present in the occluded vessel endo-
thelium is lacking in oxygen and altogether with the changes in vascular pressure generate a
major reactive oxygen species (ROS) production [22] that promotes higher expression of:
Matrix metalloproteinases 2 and 9 (MMP 2 and 9) that digest the basal endothelial sheet [23]
and cyclooxygenase 2 (COX-2) and subsequent prostanoid production [24]. Increased ROS
production also cause complement and endothelial cell activation that promotes the secretion
of proinflammatory mediators such as IL-1 and IL-6, and increased expression of intercellular
adhesion molecule (ICAM), vascular adhesion molecule (VCAM), and leukocyte adhesion
receptors such as selectins P, E, and L; all this promotes leukocyte adherence and extravasation
[25].
When, or if the occlusion is not permanent, the vessel experiences reperfusion (spontaneously
or after treatment). During this process blood flow is restored, thus once again providing
glucose and oxygen to the already injured tissue. This situation worsens neural tissue damage
as a result of an increase in substrate availability that causes an increment of free radical
production, lipoperoxidation, and a rise in cell death protein activation, as well as adhesion
molecules [26] and metabolic detriment [27].
As free radicals such as nitric oxide (NO) and ROS increase, they interact with their target
molecules and activate mechanisms such as apoptosis, arachidonic acid metabolism, and
respiratory chain inhibition that, as a consequence, increase inflammatory mediators [26, 27]
that contribute to the secondary degeneration.
Although it is worth mentioning that the amount of neural damage depends on how long the
vessel is occluded, since it has been observed in several studies that early reperfusion reduces
infarct sizes [27].
3. Secondary degeneration due to inflammation
Microglia is specialized macrophages that live in the cerebral parenchyma, when at rest or
quiescent, these normally exhibit a phenotype characterized by thin processes. These cells are
also very sensitive to changes in the cerebral milieu since their primary functions are to
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eliminate cell debris from apoptosis [28], regulate neural synapses [29], neurogenesis [30],
trophic factor production [30], inflammatory process [31], damaged cell phagocytosis, and the
repair and remodeling processes of the central nervous system (CNS) [32].
During early stages of ischemia, when there is a progressive decrease in oxygen and ATP in
the cerebral parenchyma, glial cells release molecules such as lipocalin 2 (LCN2) [33] and IL-4
[34] secreted by neurons as an immediate response to injury. These molecules are capable of
activating microglia and induce a protective M2 phenotype characterized by the production
of anti-inflammatory cytokines IL-10, IL-4, and increased phagocytosis [33]. This phenotype
has been observed during the first 7 days post-ischemia; it reaches it max peak at 3–5 days,
and decreases by day 14, suggesting that microglia promotes neuronal survival during this
first stage by attempting to reduce inflammatory mediator release by synthesizing transform-
ing growth factor-β (TGF-β), arg-1, and CD206 [35, 36], apart from producing growth factors
such as insulin-like growth factor-1 (IGF-1) and ciliary neurotrophic factor (CNTF) that
facilitate mechanisms of repair [34].
While the milieu changes from day 3 through day 14 post ischemia toward high concentrations
of Ca2+, free radicals, glutamate, and debris from neuronal necrosis, microglial phenotype
gradually changes from M2 to M1, and begins to express genes such as nitric oxide synthase
(INOS), CD16 and CD32 as well surface markers such as CD11b and MCHII [36]. M1 phenotype
is distinguished by a decrease in phagocytosis activity and an increase in the production of
proinflammatory mediators: IL-1β, IL-6, and tumor necrosis factor α (TNF-α) and an increase
in NO, H2O2, ROS, MMPs, and chemokines such as CXCL10, CCL2, MCP-1, CXCL1, and CCL5
[35, 37]; through the Notch pathway signaling [38], all of which propitiate the support for a
proinflammatory milieu.
This polarization of microglial activation gives rise to the opportunity to search for ways to
modulate it in order to induce an M2 phenotype and through it, be able to get the beneficial
effects of an anti-inflammatory milieu, accompanied by trophic factors that ease cellular repair.
On the other hand, macrophages and mast cells dwell around the cerebral parenchyma and
the perivascular spaces, also called Virchow-Robin spaces, these cells activate in presence of
inflammatory mediators secreted as a result of ischemia/reperfusion [39, 40]. These produce
high concentrations of histamine, catepsines, matrix metalloproteinases that further contribute
to endothelial damage, blood-brain barrier (BBB), hyperpermeability, and the vasogenic edema
formation as well increased production of TNF-α and CXCR, CXCL1/2/3 chemokines that will
promote massive leukocyte recruitment to the perivascular region [39, 41], specifically
neutrophils monocytes and T lymphocytes.
Neutrophil arrival at the injured perivascular space depends on time and type of occlusion,
Nina Vindegaard Groberg et al. published in 2013 that when the occlusion lasts 120 min, there
is an important number of neutrophils that arrive 12 h post-ischemia, reaching a peak con-
centration at 24 h; when the occlusion lasts 60 min concentration peak is observed as far as 3
days post-ischemia [42]. Notwithstanding, Isabel Pérez de Puig et al. results published in 2015
point out neutrophil presence as early as 6 h post-ischemia in permanent MCA occlusion
(MCAo), which opens to consideration the fact that neutrophil quantity and distribution are
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different among patients [43]. Nevertheless, postmortem tissue analysis from people who
suffered from cerebral ischemia in various vessels yielded no difference in neutrophil amount
in perivascular zones, leptomeninges, and cerebral parenchyma around the lesion site.
As neutrophils arrive to the injury site, they react almost immediately to damage-associated
molecular patterns (DAMPS), TNF-α and Interferon gamma (INF-γ) which are found widely
distributed around the perivascular zone and cerebral parenchyma. This promotes their
activation, and thus, they acquire the ability to secrete cytokines, primarily IL-1β, IL-6, also
lytic enzymes, free radicals, and angiogenic factors, as well as chemokines such as CXCL9 and
CXCL10 which influence Th1 and Th17 lymphocyte migration [44, 45], triggering an increased
amount of cells and a proinflammatory milieu.
In the clinical field, it has been observed that patients who suffered from cognitive deterioration
after an ischemic event have high concentrations of neutrophils, showing a high correlation
between the degree of tissue damage secondary to inflammation and functional recovery [46].
Even patients that have been treated with recombinant tissue plasminogen activator (rtPA) but
that previously presented high neutrophil amount have had the worst results associated with
neuroprotection exerted by rtPA [47].
Large efforts are being made to conduct scientific investigations oriented toward the decrease
of secondary damage through the inhibition neutrophil recruitment, the adherence of these to
endothelial cells through cannabinoid 2 (CB2) receptor activation [48], or through Neurogenin1
(NRG1) growth factor that reduces response to endothelial inflammation causing a decrease
in ICAM-1, VCAM-1, and selectin E [49] or by the use of competitive antagonist CXR2/CXR3
[50] all of which have demonstrated to have beneficial effects in the decrease of infarct size in
animals subjected to these treatments.
Nonetheless, in the clinical setting, the use of some molecules such as Enlimomab, which
reduces leukocyte adhesion, have had negative effects in stroke patients because it made them
more prone to suffer from secondary infections that increased complications during their
recovery [47].
In response to CCL2, MCP-1, and CXCL1 chemokines, to mention a few, monocytes infiltrate
into the perivascular and brain tissue, and as thought up to a few years ago, they differentiated
in macrophages indistinguishable from activated microglia, stimulating and exacerbating
brain injury [51]; nonetheless, thanks to the identification of different monocyte subtypes
investigators have been able to identify some of their roles in the injured tissue.
Recently, two different monocyte population types that express different markers have been
identified in mice. Classical or proinflammatory monocytes expressing Ly-6Chigh, CCR2high, and
CX3CR1low markers have short half-lives and are actively recruited into inflamed tissues,
boosting inflammation. The other types, expressing Ly-6Clow, CCR2low, and CX3CR1high
markers, have longer half-lives and are found inspecting vessel integrity, aiding its mainte-
nance [52]. Trying to identify the precise roles of each type of monocyte subpopulation is an
essential task, since in 2015, Ritzel and his team conducted an experiment in which they
demonstrate that 90 min after ischemia; there is a large forfeiture of microglia and a very high
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rise in monocytes coming from the periphery and reach up to 90% of monocytes in the ischemic
brain at 72 h post-ischemia, making evident their very important role in injured tissue [53].
Several studies conducted in mice have also demonstrated that the rise of monocytes in blood
and cerebral tissue express pro inflammatory markers, from subpopulation Ly-6Chigh during
the acute phase of ischemia [52, 53]. The rise of this subpopulation is correlated with the infarct
size and neurological deficit in mice subjected to ischemia/reperfusion [54]. Also, a rise in TNF-
α and IL-1β production, characteristic of this subtype, is observed during the first 72 h post-
ischemia [53]. Nonetheless, it has also been observed that there is a change of phenotype during
monocyte differentiation into macrophages, acquiring anti-inflammatory characteristics along
with the synthesis of TGF-β around the sixth day post-ischemia [55, 56]; but it is still not clear
how such differentiation occurs, or what characteristics induce the process.
Experimentally, it has been observed that T lymphocytes reach the cerebral parenchyma later
in time, between 24 and 96 h post-ischemia, reaching a max peak at 3–7 days post-ischemia [57,
58]. The increase of monocyte differentiation into macrophage infiltration, the expression of
major histocompatibility complex II (MHCII), and costimulatory molecules in the activated
microglia and the presence of CNS antigens such as myelin basic protein (MBP), NR2A/2B
subtype of the N-methyl-d-aspartate receptor) and the human neuron-specific enolase (NSE)
to mention a few, all products of necrosis and neural cell rupture found in systemic circulation
and brain parenchyma [59, 60] stimulate antigen presentation. It is worth mentioning that at
clinical level, concentration of these proteins has been related to the severity of neurological
damage and extent of brain lesion in humans [61].
The characteristics of the immune response to these antigens that have modified their nature
due to the degree of necrosis resulting from ischemia, differ depending on the presented
epitope [62]. Different from other CNS pathologies, in ischemia, Th1-type immune response
to antigens like MBP is infrequent, but exacerbated when exposed in combination to lipopo-
lysaccharides (LPS), since secondary-to-stroke infections are very common [62]. Nonetheless,
it has not been possible to clearly establish which mechanism of autoantigens is involved in
damage exacerbation.
There are a series of experiments that show the harmful role of T lymphocytes, among which
are those performed by Gokhan [26] and his team in 2006 where they observed that lympho-
cytes are the primary producers of INF-γ and other proinflammatory cytokines, that promotes
an increment in infarct size [26]; and those performed by Liesz in 2011 [63], in which they
observed that by eliminating lymphocytes, infarct size was reduced in animals subjected to
cerebral ischemia, all of which matches with Xiong et al.’s results in 2013 [64], where they
observed that T lymphocyte deficiency significantly reduces infarct volume in a transient
cerebral ischemia model, but not in distal permanent occlusion, which highlights that the
model and level of reperfusion used are essential and differential to evaluate damage.
Thanks to new arrangement of more specific cellular markers, some new functions and
mechanisms have been identified during stroke for the different T cell subtypes. INF-γ
production, primarily by T CD4+ cells, is what fundamentally compromises injury exacerba-
tion [63]. T CD8+ cell activation conducts to neural cell death through perforin-granzyme
Immune System Involvement in the Degeneration, Neuroprotection, and Restoration after Stroke
http://dx.doi.org/10.5772/64318
113
pathway. Natural killer (NK) cells have a less noxious effect. T γδ cells show an injurious effect
at the experimental level through the production of IL-17, IL-23 [38, 63, 64] and IL-6 at the
clinical level [65]. Treg lymphocytes have been implicated mostly in neural tissue protection,
preventing autoimmunity and inflammation through IL-10 [66].
Immune tolerance to autoantigens is based on the regulation of autoreactive T lymphocytes
through various mechanisms involving: elimination, anergy, or suppression via Treg cells,
even though several studies have not found benefit from them, since after being eliminated,
injured tissue did not present further damage [65].
Recent studies have observed that autoreactive T cells have the ability to promote neuropro-
tection. This physiological mechanism appears when the CNS suffers from damage and can
be potentiated or modulated through active immunization with neural-derived peptides. Such
has been demonstrated in several models, like: spinal cord injury [66], multiple sclerosis [67],
partial injury to the optic nerve [68], among others. Using T lymphocytes for the bone mor-
phogenic protein (BMP) autoantigen neuroprotection is observed, under morphological,
anatomical and functional criteria. Through this immunomodulation mechanism, a major
production of anti-inflammatory cytokines and trophic factors has been observed, which is a
crucial event to look for in neuroprotection and even neurorestoration.
Each comprised mechanism of immune system participation in cerebral ischemia represents
an opportunity to explore immunomodulation and contention that shall not be wasted, in
order to look for tissue neuroprotection and neurorestoration.
4. Inhibition of immune response as a neuroprotective mechanism
The cytokine accumulation and cellular infiltration increase mentioned above drive an
expansion in damage, even though molecules that try to limit it are released. This prejudicial
effect increases in relation to passing time and ischemia intensity, which provides a relatively
small therapeutic window to look for protection alternatives. Initially, because the immune
system has always been considered as one of the responsible mechanisms for damage increase,
most neuroprotective therapies are being investigated toward its inhibition, looking to
eliminate proinflammatory cytokine production and cell recruitment.
For this reason, strategies to try and delay or stop the biochemical and molecular damaging
process are being investigated since over four decades ago in preclinical phases [69, 70] using
different compounds that exert neuroprotective mechanisms.
Neuroprotection is a term that refers to the use of different therapies, alone or in combination
that protect the brain or the neural cells against damage from immune degeneration, apoptosis,
and dysfunction [70, 71].
Neuroprotection is aimed at not only protecting neurons, but also other brain constituents,
such as microglia and endothelial cells of the penumbra region [72], and can be achieved
through different mechanisms such as: anti-excitotoxic agents, anti-inflammatory agents,
antioxidants [71], but our main focus will be in those that are involved with the immune system.
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Studies have been conducted in different settings and performed in animals in order to prove
the existence neuroprotective characteristics of several molecules through all of these different
mechanisms, focusing on those with immunomodulatory and immune inhibition activity [73].
Among those studied, the most recent substances that have demonstrated to have neuropro-
tective mechanisms through anti-inflammatory activity in the preclinical field, the following
are included.
Lycium barbarum polysaccharides are derived from a traditional Chinese plant that when used
in a stroke model in mice, the investigators observed a reduced number of apoptotic cells in
the peri-infarct zone, as well as a reduction in neurological deficit. This extract has neuropro-
tective effects through the inhibition of the ERK and JRK pathways, it inhibits MMP-9 and thus
protect the BBB integrity, and it also regulates aquaporin-4 in order to reduce brain edema [74].
Piperine (1-peperoylpiperidine) is an extract from pepper usually used in folk medicine to treat
different ailments since it appears to be anti-inflammatory. A group led by F. Islam investigated
its effect in ischemic brain injury. They pretreated Wistar rats and investigated its neuropro-
tective role in a period of 24 h after the MCAo and observed a down regulation of COX-2, nitric
oxide synthase (NOS-2), and nuclear factor κβ (NF-κβ) in the penumbra region, thus reducing
the secretion of proinflammatory cytokines. A decrease in infarct size and less neuronal loss
was also observed in the pretreated group [75].
Simvastatin is a pharmacological agent used in the treatment of atherosclerosis and high blood
cholesterol, it has shown neuroprotective effects in ischemic brain injury through the upregu-
lation of Nitric Oxide synthase, decrease in ROS production, the fibrinolysis activation through
the upregulation of tissue plasminogen activator (tPA), and downregulation of plasminogen
activator inhibitor-1 (PAI-1), as well as the recruitment of inflammatory components of the
ischemic cascade from monocytes, macrophages, and T lymphocytes [76].
Neuro-erythropoietin (EPO) has proven to be neuroprotective in ischemic models. It decreases
susceptibility to glutamate toxicity and nitric oxide, thus being antioxidant, it also induces the
production of ant apoptotic and neurotrophic factors and decreases inflammation. Another
proposed mechanism for neuroprotection by EPO is the use of the released iron by the ischemic
lesion for erythropoiesis, thus limiting its oxidative effects [77].
Levodopa/benserazide is a pharmacological agent that during an investigation was given to
rats 2 days after experimental stroke, and at day 7, T cells and chemokines were analyzed. It
was discovered that CD3 and CD8 T cell population was diminished in the treated group, as
well as lower levels of ICAM-1 in the ischemic hemisphere [78].
Fingolimod modulates the activity of the membrane receptor (S1PR) responsible for the
reduction in lymphocyte migration into the brain tissue and the microvasculature; this
increases cerebral blood flow by attenuation of adhesion and thrombus formation and protects
the brain indirectly [79].
Other molecules occurring naturally, such as fatty acids, have neuroprotective effects through
immunomodulation and antioxidation. Omega-3 fatty acids are essential for human consump-
tion since humans lack the ability to synthesize them. In vivo and in vitro experiments per-
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formed by Zhang et al. using fish oils and/or omega-3 fatty acids demonstrate the importance
of their consumption since the animals treated and subjected to MCAo showed lesser infarct
size and neurological deficit. The mechanisms proposed by these authors are antioxidation
through the enhancement of the expression of hemeoxigenase-1 (HO-1) and nuclear translo-
cation of Nrf 2 in the in vitro model. The in vitro experiment showed increased levels of HO-1
in microglia and astrocytes, and they later proved its involvement in neuroprotection after
stroke. Other studies have also shown that they exhibit anti-inflammatory properties, reduce
microglial activation, and inhibit neutrophil activation. Altogether, they found that fish oil and
omega-3 enriched diets have neuroprotective effects since treated animals showed less infarct
size and neurological deficit, and treated cultures showed increased cellular viability [80].
5. Modulation of immune response as a therapy for stroke
Immunomodulation refers to the therapeutic approach to alter or modify the immune response
for the benefit of the patient. Cytokine production, e change in cellular phenotype, and the
complement are manipulated to modify the milieu to which the immune system shall react
[81]. Immunomodulation can also be achieved through induction of anti-inflammatory milieu
(L-4, TGF-β, other cytokines) in which Tregs and microglia can be induced toward a beneficial
response.
The immunomodulation area of study is being increasingly explored, having already found a
great diversity in pharmacological proposals that induce this type of response, among which
we can mention: Ganoderma lucidum, another traditional Chinese plant extract has been used
too in ischemic models with neuroprotective effects. This extract has shown these beneficial
effects through the decrease of TNF-α and IL-8 and IL-6, as well as MDA levels in the hippo-
campus, and increases levels of IL-2, IL-4, and IL-10, all of which reduces neuronal loss. On
the other side, it has antioxidant effects through the increase of superoxide dismutase activity.
Overall, it reduces neurological deficit and the infarct size [82].
Yang et al. demonstrate that by treating animals with minocycline previous to an ischemic
event increases blood flow, increases tight junction protein concentration in the ischemic
cortex, maintained levels of MMP 2, 9, and 3 needed for repair. It also decreased microglial/
macrophage activation, compared to the non-treated group, and activation was alternate at 4
weeks, meaning that microglia/macrophage expressed phenotype M2. This supports the
observed decrease in TNF-α and IL-1β and increase in TGF-β and IL-10. Animals treated with
minocycline Chad lesser infarct sizes assessed by MRI and (2,3,5-Triphenyltetrazolium
chloride) TTC staining [83].
IL-4 is a naturally occurring cytokine produced mainly by Th2 cells, mast cells, eosinophils,
and basophils. It is thought to be essential for the promotion of macrophage phenotype
differentiation toward an M2 response, rather than the classical M1. IL-4 production reduces
over time, and this is associated with neurodegenerative diseases. Liu and his team proved
the importance of IL-4 after acute ischemic stroke, since IL-4 Knockout (KO) mice exhibited
greater tissue loss at day 5 and functional deficit including memory impairment and spatial
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learning decrease. Overall, they suggest that immunomodulation IL-4 plays a key role in
recovery after stroke [84].
Another cytokine involved in immune modulation and anti-inflammation is INF-β. It has been
already approved by the FDA for MS treatment and Kuo et al. studied it for experimental
stroke, demonstrating a protective effect, since animals treated had less infarct volume and
neurological scores. The authors suggest that this is mediated through the INF-β receptor, since
animals lacking this receptor (Ifnar1−/− MCAO/R mice) showed no protective effect from the
treatment. The mechanisms involved in INF-β neuroprotection are: decrease in inflammatory
cytokine expression (IL-1β, IL?6, IL-23p19, and TNF-α), reduction in microglial activation and
soma size (suggestive of resting state), decrease in macrophage/monocyte, CD4+ and γδ T cell
and neutrophil infiltration, inhibits TNF-α induced ICAM-1 (but not VCAM-1) and E selectin
upregulation and inhibition of MMP-9, CCL3 and CXCL3 [85].
Under the bases of the new concept conceived by Dr. Michal Schwartz “protective autoim-
munity,” various non-encephalitogenic peptides have been tested. These have shown to
potentiate neuroprotective effects of the immune system itself, such as Cop-1 is a modified
neural peptide used in the treatment of multiple sclerosis that has shown beneficial effects in
previous stroke models. Cop-1 competes for binding to MHCII since it has a high, fast, and
efficient binding to several MHC molecules in several murine and human antigen-presenting
cells without the need of being processed. It is also a MBP epitope 82-100 antagonist, which
present a high cross-reaction with this molecule, thus competing with it for the MHC binding
site. This copolymer helps modify the milieu since immunization with COP-1 after stroke has
shown to induce a Th2 response [86]. Overall, these changes provide an anti-inflammatory
milieu (cytokine production: IL-4, IL-5, IL-10, and TGF-β). Under this background effect of
Cop-1 in MCAo model where rats were immunized with this neuropeptide after being
subjected to the occlusion. Results analyzed 7 days post-ischemia yielded a decreased infarct
size and lesser neurological deficit in animals treated with Cop-1, results consisting with
neuroprotective benefits [87].
Poly-YE is a high molecular weight copolymer that has proven to exert immunomodulatory
effects through the downregulation of Treg, modulation of microglial and macrophage
response in the thalamus and an increase in production of insulin-like growth factor-1 (IGF-1)
by Nestin+ cells. After subjecting rats to experimental stroke, those treated with poly-YE
presented diminished infarct size and neurological deficit [88].
Myelin oligodendrocyte glycoprotein (MOG) administered nasally demonstrated reduction
in infarct size through the induction of IL-10-secreting CD4+ T regulatory cells and reduc-
tion of CD11b+ cells which contribute to the NO synthesis. Overall, infarct size and neuro-
logical deficit were reduced by the nasal MOG administration in a MCAo stroke model
[69].
A different mechanism that has also been explored is ischemic tolerance; such consists in bring
about a pre-conditioning of the tissue, in order to promote neuroprotection [89]. Among the
activated mechanisms are an increase in anti-inflammatory cytokines such as IL-4 and IL-13
that ease hippocampal pyramidal neuron survival after an ischemic event in gerbils [90]. Tu
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XK and his team also demonstrated that neuroprotection can be originated by pre-conditioning
through modulation of the phosphatidyl inositol 3-kinase (PI3K/Akt) and ERK1/2 pathway
modulation [91] (Table 1).
Therapy  Mechanism of neuroprotection
↑Increase
↓Decrease 
Treatment outcome  Reference 
Lycium barbarum  • Inhibition of proinflammatory
pathway
• ⇥MMP-9
• Regulation of aquaporin-4
 
Reduction in the number of
apoptotic cells in the peri-infarct
zone
Reduction of edema
Decreased neurological deficit 
Yang et al. 2012 
Piperine (1-
peperoylpiperidine) 
• Immunomodulation:
↓COX-2, NOS-2, and NF-kB
 
Decrease in infarct size and
neuronal loss 
Vaibhav et al.
2012 
Simvastatin  • Immunomodulation:
recruitment and modulation of
macrophage, monocyte,
and T lymphocyte activity
Antioxidation: ↑NO
synthase, ↓ROS
• ↑Blood flow: ↑tPA →PAI-1
 
Reduce changes in BBB and
protect brain against cell stress
Reduced amounts of
inflammatory proteins in the
brain 
Campos-Martorell
et al. 2014 
Neuro-EPO  • Neurotrophic effects
• ↓Glutamate NO,
use of released Iron
• Anti-Inflammation
 
Higher survival in treated
animals, reduced neurological
deficit.
Increased histological protection 
Lagarto Parra et al.
2012 
Levodopa/
Benserazide 
• Immunomodulation:
↓CD3, CD8 T cells.
• ↓ICAM-1.
 
Attenuation of inflammation,
reduced number to T cells,
reduced ICAM-1, and T cell-
associated IL-5. 
Kuric et al. 2014 
Fingolimod (FYT720)  • Immunomodulation:
↓lymphocyte migration
through ↓S1PR
• ↑Blood flow: ↓adhesion
molecules, ↓thrombi
 
Reduction of infarct size
Reduction of lymphocytes in
cerebral vasculature→increased
blood flow 
Kraft et al 2012 
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Therapy  Mechanism of neuroprotection
↑Increase
↓Decrease 
Treatment outcome  Reference 
Omega-3  • Anti-inflammation: →
proinflammatory cytokines
• Antioxidation:
↑Hemeoxigenase-1,
Nrf2
• ↓Neutrophil infiltration,
microglial activation
 
Reduction of infarct size
Reduced neurological deficit
Increased cell viability (in vitro) 
Zhang et al. 2014 
Ganoderma lucidum  • Immunomodulation: ↓TNF-α,
IL-8, IL-6. ↑IL-2, IL-4, IL-10
• Antioxidation: ↑superoxide
dismutase activity
 
Reduction of infarct size
Reduced neurological deficit 
Zhang et al. 2014 
Minocycline  • ↑Blood flow
• Immunomodulation: M2
phenotype, maintenance
of MMP’s, ↓TNF-α, IL-1β,
↑TGF-β, IL-10
 
Reduction of infarct size  Yang et al. 2015 
IL-4  • Immunomodulation:
↑M2 phenotype ↓M1 phenotype
 
Decreased tissue loss
Better spatial learning and
memory 
Zhao X, et al.
(2015) 
INF-β  • Immunomodulation: ↓MMP-9
• ↓Iba1 cells, ↓ TNF-α, IL-1b, IL-6
• ↓Adhesion molecules, selectin E
• ↓Monocyte, macrophages
 
Reduction of infarct size
Decreased neurological deficit 
Kuo PC, et al.
(2016) 
Cop-1  • Immunomodulation: ↑Th2 reg
response. ↑IL-4, IL-5, IL-10,
↑M2 microglial phenotype
 
Reduction of infarct size
Decreased neurological deficit 
A. Ibarra et al.
2007 
Poly-YE  • Immunomodulation:
↓Treg, modulation of microglial
and macrophage response
• ↑IGF-1
Reduction of infarct size
Decreased neurological deficit 
Ziv et al. 2007  
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Therapy  Mechanism of neuroprotection
↑Increase
↓Decrease 
Treatment outcome  Reference 
 
MOG  • Immunomodulation:
↑IL-10-secreting CD4+ Treg
• ↓CD11b+, ↓NO
 
Reduction of infarct size
Decreased neurological deficit 
Frenkel et al.
2004 
IL-10  • ↑Stem cell proliferation
 
Neurogenesis  Wang et al 2015 
Noggin  • Modify activated microglial
phenotype from M1 to M2
 
Neurogenesis and angiogenesis  Shin et al, 2014 
Antibodies  • Inhibit signaling pathways that
limit axonal growth
 
Increased neuroplasticity and
neurological recovery 
Weissner et al,
2003. 
ALA  • Anti-inflammaton: ↓: IL-1 β,
TNF-α, MIP1, Iba-1
• ↑SOX2
 
Reduction of infarct size
Increased neurological recovery 
Choi et al, 2015 
Tetrmetylpyrazine  • Anti-inflammatory
• Antioxidant
 
Induce dendritic plasticity
Greater neurological recovery 
Lin et al, 2015 
Ischemic pre-
conditioning 
• Anti-inflammation: ↑IL-4, IL-13
• Pathways: PI3K/Akt)
and ERK1/2
 
Reduction of infarct size  Schaller et al. 2003
 
    Increased neurological recovery  Tu XK et al 2015 
    Pyramidal neuron survival  Kim DW et al
2015 
Table 1. Neuroprotective mechanisms exerted by diverse therapies.
6. Immune response as a neurorestorative mechanism
Even though neuroprotection is a targeted treatment that might be useful in a variety of
ailments above mentioned, it does not restore tissue to its original anatomical state. In order
to achieve “anatomical normality,” alternative and promising therapies are being studied for
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achieving neurorestoration through different mechanisms [71] involving the immune system,
given that these new strategies have shown that immune cells are able to secrete factors that
intervene in neurorestoration processes like neurogenesis.
Different studies have demonstrated that autoreactive T lymphocytes support neurogenesis
in young and old animals, and are essential for memory development and spatial learning [92].
This was observed before by studies where the circulating T lymphocyte depletion drives a
cognitive deficit from neurogenesis decrease [93].
Active immunization with Cop-1 has demonstrated to be able to increase trophic factor
production, such as: IGF-1 in retinal ganglion cells [94] experimental autoimmune encephalitis
(EAE) [95], as well as in combination neurotrophin-3 and neurotrophin-4 (NT-3 and NT-4) in
EAE [96].
Both brain-derived neurotrophic factor (BDNF) and NT-3/NT-4 have been implicated in
neurogenesis regulation mechanisms, differentiation, and neuron survival through its
receptors Trks or p75 [97], also, BDNF has been implicated in neuroblast migration processes
through the rostral migratory stream [98]. In healthy conditions, neuroblasts are conducted to
the olphactory bulb where they mature and contribute to site plasticity [99], or in pathological
conditions such as ischemia, they can be conducted toward periphery of the damage zone
where they incorporate.
IGF also promotes neural cell proliferation by interacting with its receptor IGF-IR in the sub-
ventricular zone as well as the hippocampal dentate gyrus (neurogenic niches in adults) in
adult rats [100]. Furthermore, it participates in oligodendrogenesis after being stimulated by
Cop-1 in a multiple sclerosis model [95].
Immunization with Cop-1 has demonstrated to induce an increment in neurogenesis and
neuron survival during acute and chronic phases of an ischemic event [101]. In the same way,
Poli-Y immunomodulator has also shown an increment in cortical and hippocampal neuro-
genesis, as well as reduction of neural loss [88].
IL-10 use has also shown to have a positive effect on neurogenesis after cerebral ischemia, in
2015 Wang J and his work team observed that Treg cells are capable of increasing stem cell
proliferation in the sub ventricular zone through IL-10 production [102].
Noggin is a bone morphogenic protein (BMP) antagonist that has also been tested in a MCAo
model and has had neuroprotective as well as neurorestorative results through its ability to
modify activated microglial response from M1 to M2 phenotype and induce an increase in
several molecule production such as: vascular endothelial growth factor IL-10, Growth
Associated Protein-43 (GAP-43), and vascular endothelial growth factor (VEGF) which
intervene in neurogenesis and angiogenesis [103].
Antibodies have also been used successfully to inhibit signaling pathways that limit axonal
and neurite growth and remodeling, thus allowing an increment neuronal plasticity and
neurological recovery in ischemic rats [104].
On the other hand, the use of cell-based therapies is being studied for their neurorestorative
properties; for instance, it has been demonstrated that microglia participates in neuronal
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precursor cell (NPC) migration and differentiation [105], as well as in neurogenesis, synapto-
genesis, and tissue remodeling increase through the release of IGF-1 and neurotrophic growth
factor (NGF), among others, in animals subjected to experimental stroke [106].
Other animal models, such as traumatic brain injury (TBI), have had success in the use of
combined therapies composed of stem cell co-transplants and pharmacological a or immuno-
modulatory agents that modify neural tissue milieu in order to favor recovery and restoration.
For example, the use of granulocyte-colony stimulating factor (GCSF) and human umbilical
cord blood cell (hUCB) transplantation has demonstrated to reduce proinflammatory cytokine
expression, increases trophic factor production, and promotes synaptic circuit reestablish-
ment. For this reasons, it has been proposed as a therapy for stroke models [107].
Another mechanism through which brain tissue restoration is pursued is neuroplasticity or
synapse plasticity, which is an inherent neurophysiological adaptive trait in which preexisting
connections between two neurons can gain or lose strength during neural activity [108], as well
as change in structure, function and organization [109]. It responds to different experiences
and emphaticism and has been observed in different sections of the CNS [109].
Treatment with tetramethylpyrazine, which has anti-inflammatory and antioxidant effects, has
shown to be able to induce dendritic plasticity, observing maintenance of neuroarchitecture
through microtubule-associated protein 2 (MAP-2), which has been observed in greater
density in peri-infarct zone found dendrites, causing a greater neurological recovery in rats
with cerebral ischemia [110].
Alpha-lipoic acid (aLA) has yielded very good results in preclinical investigation since it has
shown that its anti-inflammatory capacity through a decrease in proinflammatory cytokine
expression such as: IL-1β, TNF-α, MIP1, Iba-1, and the increase in expression of transcription
factor SOX2, which is essential for maintenance of auto regeneration properties, as well as an
increase in neuron precursor cell proliferation accompanied by a significant reduction in infarct
volume and better functional recovery. For all these reasons, aLA is a great candidate to start
clinical trials as neurorestorative of brain tissue [111].
7. Advances in the clinical field
Even though preclinical trials have yielded promising results, translation into clinical human
stroke trials has been unsuccessful. Clinical trials have been conducted very scarcely and have
shown very little results [72, 112]. Some agents have been used in the clinical setting after
having been observed beneficial in animal models. By 2008, Ginsberg had reported the
existence of 160 clinical trials for neuroprotection after stroke and one-third of the by-then-
finished 120 trials included more than 200 subjects; nonetheless, most of them failed to prove
any benefit [70]. As of March 2016, a search in “www.strokecenter.org” for clinical trials
involving neuroprotection yields 25 results of which 12 involve neuroprotection for acute
ischemic stroke and only one of them is already in already phase 4. A different search in
involving the word “immune” yielded another 25 matches, of which only two are related to
immunomodulation in stroke.
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One of them, Nasal Selectin E administration is being studied by Hellenbeck, M.D. at the
National Institute of Neurological Disorders and Stroke (NINDS) in patients that have suffered
from stroke, seeking induction of mucosal tolerance to this adhesion molecule through low-
dose nasal administration, in order to promote a response shift from Th1 toward Th2 or Th reg
at inflammation sites. This trial is currently at phase I and has not yet published results [113].
Fingolimod, which has been mentioned earlier, is also being used in an ongoing clinical trial
with the goal of analyzing neurofunctional effects in stroke patients at different time points
after being orally administered. The secondary purpose is to identify if there are any cellular
and structural brain modifications through the use of flow cytometry and MRI [114].
In accordance, a pilot trial was conducted combining the use of rtPA and Fingolimod in a
randomized multicenter pilot trial that included 47 patients in China. Treatment was provided
within 3 and 3.1 h from symptom onset. Whole blood was used to assess lymphocyte and
mononuclear cells at day 1, 7, and 90. After day 1, CD4+ T cells, CD8+ T cells, CD19B+ cells, and
NK cells had significant decreases in the fingolimod + alteplase group, as opposed to the
alteplase only group. At day 7, this trend continued and normalized by day 90th. Other results
included lesser infarct volume expansion, smaller hemorrhage, and greater functional
recovery in the short and long term in the combined treatment group. Safety was assured
during this trial, and further investigation needs to be considered [115].
On the other hand, stem cell therapies are also under clinical scrutiny, their use has proven to
be feasible, but not necessarily practical, and it is safe. Most clinical trials have proven that
stem cell therapy improves functional recovery but other factors have to be taken into account
too, such as cost-effectiveness, comparison to other stroke treatments, time, and type of stroke.
According to Young, there are currently nine ongoing stem cell clinical trials for stroke, testing
safety, and efficacy as well as most accurate patient selection [116].
Knowledge about the molecular dynamics of cerebral ischemia pathophysiology and the study
of neuroprotective mechanisms has promoted the use of combined therapies [89].
The use of combined therapies has also been tried in the clinical field in different diseases. For
example, two quadriplegic patients were transplanted with differentiated neural stem cells
(NSC) and autoreactive autologous T lymphocytes. These patients regained motor and
sensitive functions without adverse effects [117], all the more reason to try these therapies in
stroke.
Some stem cell trials have shown to have some beneficial effects on stroke patients, such as the
use of human placenta derived adherent (PDA001) cells, isolated from postpartum placenta,
and were studied for their neurorestorative effects after stroke. Animals were injected with
these cells 4 h after being subjected to stroke. Results show an increase in functional recovery
7- and 14 days post-ischemia, as well as an increase level of BDNF, vascular endothelial growth
factor (VEGF) which is an angiogenic factor, increases axonal outgrowth, stop apoptosis and
increases neurogenesis, and hepatocyte growth factor (HGF) which is also angiogenic, and
decreased TUNEL and cleaved caspase 3, showing a decreased infarct volume. Although not
many cells survived until day 14, beneficial effects were still observed [118] (Table 2).
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Treatment  Outcome  Reference 
Nasal selectin E  Promote a response shift from Th1→Th2 or Th reg
Ongoing 
[113] 
Fingolimod  No outcome, still ongoing  [114] 
rtPA + Fingolimod  Reduced infarct volume
Greater neurological recovery 
[115] 
NSC + Autoreactive Autologous T cells  Recovery of motor and sensory functions
No adverse effects 
[117] 
PDA001  Increased functional recovery  [118] 
Table 2. Results of some clinical trials.
Most preclinical investigations focus on delivering treatment in the first hour after reperfu-
sion and happen in strictly controlled environments, which is why they have shown bene-
ficial effects. Lack of results in clinical trials is attributed to uncontrolled real life settings,
different populations, comorbidity existence, different ischemic territories, duration of oc-
clusion before reperfusion, and a single target for treatment, leaving behind other neural
components that might aid recovery. Also, patients are selected after arrival to hospitals
and thus, other environmental variables and time window are not accounted for in results
[72, 112].
The study and application of new therapies that will aid the ischemic patient recover more
effectively needs to continue to be worked on in the basic and preclinical fields, specially
through the exploration of immune system characteristics that might be beneficial for stroke
therapy and thus achieve a decrease in mortality and an increase in functional recovery after
hemiplegia (one-sided paralysis) hemi-hypoesthesia (one-sided decrease in sensory percep-
tion) hemianopsia (one eyed decreased vision), paresia (partial paralysis), aphasia (inability
to comprehend language), and memory alterations; favorably increases stroke patients quality
of life.
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